Scoop has an Ethical Paywall
Licence needed for work use Learn More

Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 

UPDATED: Fidelity pays $145M for Tower's life assets

UPDATED: Fidelity pays $145 mln in cash and liabilities for Tower’s life assets

(Updates to clarify value of transaction, adding liabilities transferred to the $70 million cash component, adds Tower share price gain)

May 10 (BusinessDesk) - Fidelity Life Assurance has acquired most of Tower’s life insurance business for about $145 million in cash and liabilities, propelling the closely held company to the third-largest in the market.

Fidelity, whose businesses include life insurance, business insurance and KiwiSaver, is acquiring most of Tower’s non-participating life insurance. The Auckland-based company has a strategy of growing organically and through acquisitions, though assets such as Tower’s life business “don’t come along very often,” said chief executive Milton Jennings.

He declined to comment on how Fidelity is funding the deal. Tower put a total “aggregate” value on the sale of $189 million including the release of capital. The actual total incurred by Fidelity of $145 million, made up of about $70 million in cash and the balance in transfer of liabilities, was confirmed by Fidelity chief financial officer Ed Eadie.

Tower’s shares rose 4.7 percent to $1.79, the highest since April 22.

Tower is retaining the capital currently held against the life insurance policies and keeping its participating book and other “run-off” insurance assets which it says are worth $23 million.

The sale marks a further step in Tower’s strategy to divest non-core assets after a strategic review, having sold Tower Investments to Fisher Funds for $79 million and its medical unit to Australia’s nib last year for $102 million, returning capital to shareholders.

Tower will now focus on its general insurance products and services, said managing director Rob Flannagan. The latest sale concludes Tower’s strategic review.

Flannagan is stepping down from his role at Tower following the completion of the listed insurer’s strategic review and asset sales. He will work out the 12 months of his notice.

(BusinessDesk)

Advertisement - scroll to continue reading

© Scoop Media

Advertisement - scroll to continue reading
 
 
 
Business Headlines | Sci-Tech Headlines

 
 
 
 
 
 
 
 
 
 
 
 
 

Join Our Free Newsletter

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.